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Background
Acute coronary syndromes arise from coronary atherosclerosis with superimposed 
thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of 
factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in 
patients with a recent acute coronary syndrome.
Methods
In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients 
with a recent acute coronary syndrome to receive twice-daily doses of either 2.5 mg 
or 5 mg of rivaroxaban or placebo for a mean of 13 months and up to 31 months. 
The primary efficacy end point was a composite of death from cardiovascular 
causes, myocardial infarction, or stroke.
Results
Rivaroxaban significantly reduced the primary efficacy end point, as compared with 
placebo, with respective rates of 8.9% and 10.7% (hazard ratio in the rivaroxaban 
group, 0.84; 95% confidence interval [CI], 0.74 to 0.96; P = 0.008), with significant 
improvement for both the twice-daily 2.5-mg dose (9.1% vs. 10.7%, P = 0.02) and 
the twice-daily 5-mg dose (8.8% vs. 10.7%, P = 0.03). The twice-daily 2.5-mg dose 
of rivaroxaban reduced the rates of death from cardiovascular causes (2.7% vs. 
4.1%, P = 0.002) and from any cause (2.9% vs. 4.5%, P = 0.002), a survival benefit 
that was not seen with the twice-daily 5-mg dose. As compared with placebo, riva-
roxaban increased the rates of major bleeding not related to coronary-artery bypass 
grafting (2.1% vs. 0.6%, P<0.001) and intracranial hemorrhage (0.6% vs. 0.2%, 
P = 0.009), without a significant increase in fatal bleeding (0.3% vs. 0.2%, P = 0.66) 
or other adverse events. The twice-daily 2.5-mg dose resulted in fewer fatal bleeding 
events than the twice-daily 5-mg dose (0.1% vs. 0.4%, P = 0.04).
Conclusions
In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of 
the composite end point of death from cardiovascular causes, myocardial infarction, 
or stroke. Rivaroxaban increased the risk of major bleeding and intracranial hemor-
rhage but not the risk of fatal bleeding. (Funded by Johnson & Johnson and Bayer 
Healthcare; ATLAS ACS 2–TIMI 51 ClinicalTrials.gov number, NCT00809965.) 
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A fter an acute coronary syndrome, patients remain at risk for recurrent cardio-vascular events despite standard medical 
therapy, including long-term antiplatelet thera-
py with aspirin and an adenosine diphosphate–
receptor inhibitor. This risk may be related in part 
to excess thrombin generation that persists be-
yond the acute presentation in such patients.1 As 
a result, there has been interest in evaluating the 
role of oral anticoagulants after an acute coronary 
syndrome. Improved cardiovascular outcomes were 
reported for patients who were treated with the 
anticoagulant warfarin in addition to aspirin.2 
However, widespread use of long-term warfarin 
in such patients has been limited by challenges 
associated with drug administration and the risk 
of bleeding. Likewise, treatment with the factor IIa 
inhibitor ximelagatran after a myocardial infarc-
tion showed cardiovascular benefits, but the drug 
was associated with hepatotoxicity.3
Rivaroxaban is an oral anticoagulant that di-
rectly and selectively inhibits factor Xa. Factor Xa 
initiates the final common pathway of the co-
agulation cascade and results in the formation 
of thrombin, which catalyzes additional coagula-
tion-related reactions and promotes platelet acti-
vation. Anti-Xa Therapy to Lower Cardiovascular 
Events in Addition to Standard Therapy in Sub-
jects with Acute Coronary Syndrome–Thromboly-
sis in Myocardial Infarction 46 (ATLAS ACS–TIMI 
46; Clini calTrials.gov number, NCT00402597) was 
a phase 2 dose-finding trial that enrolled 3491 
patients with a recent acute coronary syndrome. 
Rivaroxaban was tested at total daily doses rang-
ing from 5 to 20 mg and, as compared with pla-
cebo, reduced the composite end point of death, 
myocardial infarction, or stroke with the lowest 
hazard ratios seen at the lowest twice-daily doses, 
whereas there was a dose-dependent increase in 
bleeding events.4 On the basis of these observa-
tions, we designed a phase 3 trial, called ATLAS 
ACS 2–TIMI 51, to evaluate twice-daily rivaroxa-
ban at doses of 2.5 mg and 5 mg as adjunctive 
therapy in patients with a recent acute coronary 
syndrome, with the aim of determining a clini-
cally effective low-dose regimen.
Me thods
Study Population
The study included patients (≥18 years of age) who 
had presented with symptoms suggestive of an 
acute coronary syndrome and in whom an ST-
segment elevation myocardial infarction (STEMI), 
a non–ST-segment elevation myocardial infarc-
tion (NSTEMI), or unstable angina had been diag-
nosed. Patients who were under 55 years of age 
had either diabetes mellitus or a previous myo-
cardial infarction in addition to the index event.
Key exclusion criteria included a platelet count 
of less than 90,000 per cubic millimeter, a hemo-
globin level of less than 10 g per deciliter, or a 
creatinine clearance of less than 30 ml per minute 
at screening; clinically significant gastrointestinal 
bleeding within 12 months before randomization; 
previous intracranial hemorrhage; and previous 
ischemic stroke or transient ischemic attack in 
patients who were taking both aspirin and a thi-
enopyridine.
Study Enrollment and Randomization
Enrollment occurred within 7 days after hospital 
admission for an acute coronary syndrome. The 
condition of patients needed to be stabilized be-
fore enrollment, with the initial management 
strategies (e.g., revascularization) completed (for 
details, see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
All patients provided written informed consent.
Patients were randomly assigned in a 1:1:1 
fashion to twice-daily administration of either 
2.5 mg or 5.0 mg of rivaroxaban or placebo, with 
a maximum follow-up of 31 months. All patients 
were to receive standard medical therapy, includ-
ing low-dose aspirin; they were to receive a thi-
enopyridine (either clopidogrel or ticlopidine) 
according to the national or local guidelines. Ran-
domization was stratified on the basis of planned 
use of a thienopyridine. Patients were then to be 
seen at 4 weeks, at 12 weeks, and thereafter ev-
ery 12 weeks.
Study End Points
The primary efficacy end point was a composite 
of death from cardiovascular causes, myocardial 
infarction, or stroke (ischemic, hemorrhagic, or 
stroke of uncertain cause). The secondary efficacy 
end point was death from any cause, myocardial 
infarction, or stroke. Stent thrombosis was de-
fined according to Academic Research Consortium 
definitions.5 The primary safety end point was 
TIMI major bleeding not related to coronary-artery 
bypass grafting (CABG). Complete definitions of 
the end points have been reported previously.6 
A clinical-events committee whose members were 
unaware of study-group assignments adjudicated 
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all components of the key efficacy and safety end 
points.
Study Oversight
This randomized, double-blind, placebo-controlled, 
event-driven trial was designed as a collaboration 
between the TIMI Study Group (an academic re-
search organization), the sponsors (Johnson & 
Johnson and Bayer Healthcare), and investigators 
from the executive and steering committees (list-
ed in the Supplementary Appendix). The study de-
sign was approved by the appropriate national 
and institutional regulatory agencies and ethics 
committees.6 The study protocol is available at 
NEJM.org. An independent data and safety mon-
itoring committee monitored the trial and re-
viewed unblinded data.
The study’s sponsors coordinated data man-
agement. Statistical analyses were performed by 
the TIMI Study Group using an independent copy 
of the complete raw database. The first version 
of the manuscript was drafted by the academic 
authors of the TIMI Study Group, who take re-
sponsibility for the completeness and accuracy 
of the data and who made the decision to submit 
the manuscript for publication.
Statistical Analysis
As prespecified, efficacy analyses were performed 
with the use of a modified intention-to-treat ap-
proach, which included the randomized patients 
and the end-point events that occurred after ran-
domization and no later than the completion of 
the treatment phase of the study (i.e., the global-
treatment end date), 30 days after early permanent 
discontinuation of the study drug, or 30 days after 
randomization for patients who did not receive a 
study drug.6 Sensitivity efficacy analyses were 
conducted with the use of an intention-to-treat 
approach, which included the patients who under-
went randomization and all end-point events oc-
curring after randomization until the global-
treatment end date. The primary safety analysis 
included all patients who underwent randomiza-
tion and who received at least one dose of a study 
drug, with evaluation performed from the time of 
administration of the first dose of a study drug un-
til 2 days after the discontinuation of a study drug.
We used hazard ratios and two-sided 95% con-
fidence intervals to compare the study groups. 
Rates of the end points were expressed as Kaplan–
Meier estimates through 24 months. Testing was 
prespecified to occur between the combined-dose 
group for rivaroxaban and placebo at an alpha level 
of 0.05 on the basis of the log-rank test, stratified 
according to the intention to use a thienopyridine. 
If this comparison significantly favored rivarox-
aban, then each of the two doses of rivaroxaban 
was simultaneously compared with placebo with 
the use of a similar stratified log-rank test at an 
alpha level of 0.05 on the basis of the closed test-
ing procedure. Results were examined according to 
major subgroups for general consistency of treat-
ment effect, and interaction testing was per-
formed.
We determined that a total of 983 primary 
efficacy end-point events would provide a power 
of approximately 96% to detect a 22.5% relative 
reduction between the combined-dose group re-
ceiving rivaroxaban and the placebo group with 
a two-sided type I error rate of 0.05. The com-
parison of each of the two doses of rivaroxaban 
with placebo had a power of approximately 90% 
to determine a relative risk reduction of 22.5%.
R esult s
Patients
The study was conducted from November 2008 
through September 2011. A total of 15,526 pa-
tients underwent randomization at 766 sites in 
44 countries. The baseline characteristics of the 
patients were well matched in the study groups 
(Table 1). The index event was a STEMI in 50.3% 
of the patients, an NSTEMI in 25.6%, and unsta-
ble angina in 24.0%. The median time from the 
index event to randomization was 4.7 days (inter-
quartile range, 3.2 to 6.0). Background therapy in-
cluded the intended use of a thienopyridine in 93% 
of the patients, and the mean duration of treat-
ment with a thienopyridine was 13.3 months.
The mean duration of treatment with a study 
drug was 13.1 months. Among patients who re-
ceived at least one dose of a study drug, premature 
discontinuation of treatment occurred in 26.9% 
of patients receiving the 2.5-mg dose of rivaroxa-
ban, 29.4% receiving the 5-mg dose of rivaroxaban, 
and 26.4% receiving placebo. The most common 
reasons for discontinuation of rivaroxaban were 
adverse events and patients’ choice. During treat-
ment, the proportions of patients who were at 
least 85% compliant with the study drug were 
93.9% of patients receiving the 2.5-mg dose of ri-
varoxaban, 94.0% receiving the 5-mg dose of riva-
roxaban, and 94.6% receiving placebo. The rates 
of withdrawal of consent from the study were 
The New England Journal of Medicine 
Downloaded from nejm.org on June 9, 2016. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 366;1 nejm.org january 5, 201212
Table 1. Baseline Characteristics of the Patients.*
Characteristic Rivaroxaban
Placebo 
(N = 5176)
2.5 mg Twice Daily (N = 5174) 5 mg Twice Daily (N = 5176)
Age
Mean — yr 61.8±9.2 61.9±9.0 61.5±9.4
≥65 yr — no. (%) 1905 (36.8) 1921 (37.1) 1835 (35.5)
≥75 yr — no. (%) 466 (9.0) 441 (8.5) 498 (9.6)
Male sex — no. (%) 3875 (74.9) 3843 (74.2) 3882 (75.0)
Race — no. (%)†
White 3798 (73.4) 3815 (73.7) 3796 (73.3)
Black 34 (0.7) 34 (0.7) 39 (0.8)
Asian 1099 (21.2) 1055 (20.4) 1075 (20.8)
Other 243 (4.7) 272 (5.3) 266 (5.1)
Weight — kg
Median 78.0 78.0 78.0
Interquartile range 68.0–90.0 68.0–88.0 68.0–88.5
Creatinine clearance — ml/min‡
Median 85.1 84.8 85.6
Interquartile range 68.3–105.0 68.5–104.7 68.1–105.1
Medical history — no. (%)
Previous myocardial infarction 1363 (26.3) 1403 (27.1) 1415 (27.3)
Hypertension 3470 (67.1) 3499 (67.6) 3494 (67.5)
Diabetes 1669 (32.3) 1648 (31.8) 1647 (31.8)
Hypercholesterolemia 2498 (48.3) 2544 (49.1) 2496 (48.2)
Index diagnosis — no. (%)
STEMI 2601 (50.3) 2584 (49.9) 2632 (50.9)
NSTEMI 1321 (25.5) 1335 (25.8) 1323 (25.6)
Unstable angina 1252 (24.2) 1257 (24.3) 1221 (23.6)
PCI or CABG for index event — no. (%) 3138 (60.6) 3123 (60.3) 3126 (60.4)
Region — no. (%)
North America 269 (5.2) 293 (5.7) 312 (6.0)
South America 546 (10.6) 583 (11.3) 540 (10.4)
Western Europe 707 (13.7) 775 (15.0) 759 (14.7)
Eastern Europe 2042 (39.5) 2025 (39.1) 2007 (38.8)
Asia 1088 (21.0) 1044 (20.2) 1063 (20.5)
Other 522 (10.1) 456 (8.8) 495 (9.6)
Medications — no. (%)
Aspirin 5105 (98.7) 5099 (98.5) 5108 (98.7)
Thienopyridine 4790 (92.6) 4812 (93.0) 4811 (92.9)
Beta-blocker 3426 (66.2) 3394 (65.6) 3444 (66.5)
ACE inhibitor or ARB 2022 (39.1) 1977 (38.2) 2050 (39.6)
Statin 4304 (83.2) 4342 (83.9) 4321 (83.5)
Calcium-channel blocker 820 (15.8) 742 (14.3) 764 (14.8)
* Plus–minus values are means ±SD. There were no significant differences among the three groups. ACE denotes angio-
tensin-converting enzyme, ARB angiotensin-receptor blocker, CABG coronary-artery bypass grafting, NSTEMI, non– 
ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, and STEMI ST-segment elevation 
myocardial infarction.
† Race was self-reported.
‡ Creatinine clearance was calculated with the use of the Cockcroft–Gault equation.
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8.7% for patients receiving the 2.5-mg dose of 
rivaroxaban, 8.5% for those receiving the 5-mg 
dose of rivaroxaban, and 7.8% for those receiv-
ing placebo; and the rates of loss to follow-up 
were 0.2%, 0.3%, and 0.3%, respectively.
Efficacy End Points
Rivaroxaban significantly reduced the primary 
efficacy end point of death from cardiovascular 
causes, myocardial infarction, or stroke, as com-
pared with placebo, with rates of 8.9% and 10.7%, 
respectively (hazard ratio, 0.84; 95% confidence 
interval [CI], 0.74 to 0.96; P = 0.008) (Fig. 1). These 
results were consistent in the intention-to-treat 
analysis (P = 0.002) (Table 2). In the analysis of the 
components of the primary efficacy end point, 
rivaroxaban versus placebo had a hazard ratio of 
0.80 (P = 0.04) for death from cardiovascular 
causes (including hemorrhage-related deaths), 
0.85 (P = 0.047) for myocardial infarction, and 
1.24 (P = 0.25) for stroke (including ischemic, 
hemorrhagic, and stroke of uncertain cause).
Rivaroxaban also reduced the secondary com-
posite efficacy end point of death from any cause, 
myocardial infarction, or stroke, as compared 
with placebo, with rates of 9.2% and 11.0%, re-
spectively (hazard ratio, 0.84; 95% CI, 0.74 to 0.95; 
P = 0.006). In addition, rivaroxaban reduced the 
risk of stent thrombosis (definite, probable, or pos-
sible), as compared with placebo, with rates of 
2.3% and 2.9%, respectively (hazard ratio, 0.69; 
95% CI, 0.51 to 0.93; P = 0.02). The reduction in 
the primary efficacy end point with rivaroxaban 
was consistent among the subgroups except for 
patients with a history of stroke or transient is-
chemic attack (Fig. 2).
In the analysis of the two doses of rivaroxa-
ban, each of the doses reduced the primary ef-
ficacy end point of death from cardiovascular 
causes, myocardial infarction, or stroke, as com-
pared with placebo, with rates in patients receiv-
ing the 2.5-mg dose of 9.1% and 10.7%, respec-
tively (hazard ratio, 0.84; 95% CI, 0.72 to 0.97; 
P = 0.02) and rates in patients receiving the 5-mg 
dose of 8.8% and 10.7%, respectively (hazard ra-
tio, 0.85; 95% CI, 0.73 to 0.98; P = 0.03) (Fig. 3A and 
3B). The 2.5-mg dose of rivaroxaban, as compared 
with placebo, reduced the risk of death from car-
diovascular causes (2.7% vs. 4.1%; hazard ratio, 
0.66; 95% CI, 0.51 to 0.86; P = 0.002) (Fig. 3C) and 
the risk of death from any cause (2.9% vs. 4.5%; 
hazard ratio, 0.68; 95% CI, 0.53 to 0.87; P = 0.002). 
The 5-mg dose of rivaroxaban, as compared with 
placebo, did not significantly reduce the risk of 
death from either cardiovascular causes (hazard 
ratio, 0.94; P = 0.63) (Fig. 3D) or any cause (hazard 
ratio, 0.95; P = 0.66) and differed significantly from 
the 2.5-mg dose of rivaroxaban (P = 0.009 for both 
comparisons).
Safety End Points
Rivaroxaban significantly increased the rate of 
TIMI major bleeding that was not related to CABG, 
as compared with placebo, with rates of 2.1% and 
0.6%, respectively (hazard ratio, 3.96; 95% CI, 2.46 
to 6.38; P<0.001) (Table 2, and Fig. 1 in the Sup-
plementary Appendix), a finding that was also sig-
nificant for the 2.5-mg and 5-mg doses of riva-
roxaban (P<0.001 for both comparisons). For TIMI 
major bleeding that was not related to CABG, 
there were no significant interactions between the 
measured characteristics of patients and the study 
group (Fig. 2 in the Supplementary Appendix). 
Also greater in the combined rivaroxaban group, 
as compared with placebo, were rates of TIMI 
minor bleeding (1.3% vs. 0.5%, P = 0.003), TIMI 
bleeding requiring medical attention (14.5% vs. 
7.5%, P = <0.001), and intracranial hemorrhage 
(0.6% vs. 0.2%, P = 0.009) (Table 2). There was no 
significant difference in the rates of fatal bleed-
ing associated with rivaroxaban as compared with 
placebo (0.3% vs. 0.2%, P = 0.66).
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Figure 1. Cumulative Incidence of the Primary Efficacy End Point.
The primary efficacy end point consists of death from cardiovascular 
causes, myocardial infarction, or stroke. According to these results, the 
composite end point would be prevented in 1 patient if 56 patients were 
treated for 2 years with rivaroxaban. The P value is for the modified inten-
tion-to-treat analyses. P = 0.002 for the intention-to-treat analysis.
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In the comparison between the two doses of 
rivaroxaban, the rates of TIMI major bleeding that 
was not related to CABG tended to be lower in 
patients receiving the 2.5-mg dose than in those 
receiving the 5-mg dose (1.8% vs. 2.4%, P = 0.12), 
and the lower dose resulted in significantly lower 
rates of TIMI minor bleeding (0.9% vs. 1.6%, 
P = 0.046), TIMI bleeding requiring medical atten-
tion (12.9% vs. 16.2%, P<0.001), and fatal bleeding 
(0.1% vs. 0.4%, P = 0.04).
The rates of adverse events that were not re-
lated to bleeding were similar in the rivaroxaban 
and placebo groups (Table 1 in the Supplemen-
tary Appendix). Specifically, clinical and labora-
tory liver abnormalities were similar among pa-
tients treated with rivaroxaban or placebo, with 
alanine aminotransferase levels of more than 
three times the upper limit of the normal range 
and total bilirubin levels of more than two times 
the upper limit of the normal range occurring in 
0.2% of patients in each study group.
Discussion
Despite medical therapy after an acute coronary 
syndrome, patients continue to be at risk for re-
current cardiovascular events. In our study, riva-
roxaban significantly reduced the primary effi-
cacy end point of death from cardiovascular causes, 
myocardial infarction, or stroke in patients with 
Table 2. Kaplan–Meier Estimates and Hazard Ratios for Efficacy and Safety End Points.*
End Point Rivaroxaban
Placebo
(N = 5113)
2.5 mg  
Twice Daily
(N = 5114)
5 mg  
Twice Daily  
(N = 5115)
Combined
(N = 10,229)
Efficacy
number (percent)
Death from cardiovascular causes, myocardial in-
farction, or stroke — primary end point
313 (9.1) 313 (8.8) 626 (8.9) 376 (10.7)
Death from cardiovascular causes 94 (2.7) 132 (4.0) 226 (3.3) 143 (4.1)
Myocardial infarction 205 (6.1) 179 (4.9) 384 (5.5) 229 (6.6)
Stroke
Any 46 (1.4) 54 (1.7) 100 (1.6) 41 (1.2)
Ischemic 30 (1.0) 35 (0.9) 65 (0.9) 34 (1.0)
Death from any cause, myocardial infarction, or 
stroke — secondary end point
320 (9.3) 321 (9.1) 641 (9.2) 386 (11.0)
Death from any cause 103 (2.9) 142 (4.4) 245 (3.7) 153 (4.5)
Stent thrombosis 47 (2.2) 51 (2.3) 98 (2.3) 72 (2.9)
(N = 5115)  (N = 5110) (N = 10,225) (N = 5125)
Safety
TIMI major bleeding not associated with CABG 65 (1.8) 82 (2.4) 147 (2.1) 19 (0.6)
TIMI minor bleeding 32 (0.9) 49 (1.6) 81 (1.3) 20 (0.5)
TIMI bleeding requiring medical attention 492 (12.9) 637 (16.2) 1129 (14.5) 282 (7.5)
Intracranial hemorrhage 14 (0.4) 18 (0.7) 32 (0.6) 5 (0.2)
Fatal bleeding 6 (0.1) 15 (0.4) 21 (0.3) 9 (0.2)
* Event rates are reported as Kaplan–Meier estimates through 24 months and so are not presented as numerical percentages. 
Data for efficacy end points correspond to the modified intention-to-treat (mITT) analysis with P values presented for both 
mITT and ITT analyses. Before the unblinding of study results, 184 patients were excluded from the efficacy analysis be-
cause of violations in Good Clinical Practice guidelines at three sites. Myocardial infarction and stroke categories include fa-
tal and nonfatal events. Stroke includes ischemic, hemorrhagic, and stroke of uncertain cause. Stent thrombosis (definite, 
probable, or possible) analyses were conducted among patients who had received a stent prior to randomization. Data for 
safety end points correspond to the safety analysis. TIMI denotes Thrombolysis in Myocardial Infarction.
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a recent acute coronary syndrome. A direction-
ally consistent benefit was seen for the individual 
components of death from cardiovascular causes 
and myocardial infarction but not for stroke. The 
advantages of the addition of rivaroxaban were 
observed regardless of whether patients present-
ed with a STEMI, NSTEMI, or unstable angina 
and across the different geographical regions. 
Likewise, the two doses of rivaroxaban signifi-
cantly reduced the primary efficacy end point, 
with the twice-daily 2.5-mg dose also showing a 
survival benefit. In terms of safety, the two doses 
of rivaroxaban increased the rates of major bleed-
ing and intracranial hemorrhage, as compared 
with placebo, without a significant increase in 
fatal bleeding. The lower dose of rivaroxaban re-
sulted in less bleeding than the higher dose.
During the initial management of an acute 
coronary syndrome, parenteral anticoagulants are 
used in conjunction with antiplatelet agents.7,8 
After hospital discharge, however, antiplatelet 
medications alone have served as the mainstay 
of antithrombotic therapy. Although secondary 
prevention with oral anticoagulation has shown 
cardiovascular benefits, the regimens have been 
limited by a number of constraints.2,3 We tested 
the anticoagulant rivaroxaban in patients with a 
recent acute coronary syndrome, and the study 
met its primary efficacy end point. The factor Xa 
inhibitor rivaroxaban has predictable pharmaco-
kinetics and has not been associated with an in-
creased risk of hepatotoxicity. Rivaroxaban has 
been evaluated in a number of clinical settings, 
including the prevention and treatment of venous 
thromboembolism and stroke prophylaxis in atri-
al fibrillation.9-14
Our study was specifically designed to test 
two low doses of rivaroxaban in patients with a 
recent acute coronary syndrome. The 2.5-mg dose 
of rivaroxaban reduced the primary efficacy end 
point, as compared with placebo, and also re-
duced the risk of death from cardiovascular 
causes (relative reduction, 34%; absolute reduc-
tion, 1.4 percentage points) and from any cause 
Rivaroxaban 2.5 mg Twice Daily 
vs. Placebo
Rivaroxaban 5 mg Twice Daily 
vs. Placebo
Rivaroxaban Combined  
vs. Placebo
Hazard Ratio
(95% CI)
P Value Hazard Ratio
(95% CI)
P Value Hazard Ratio
(95% CI)
P Value
mITT ITT mITT ITT mITT ITT
0.84 (0.72–0.97) 0.02 0.007 0.85 (0.73–0.98) 0.03 0.01 0.84 (0.74–0.96) 0.008 0.002
0.66 (0.51–0.86) 0.002 0.005 0.94 (0.75–1.20) 0.63 0.57 0.80 (0.65–0.99) 0.04 0.05
0.90 (0.75–1.09) 0.27 0.09 0.79 (0.65–0.97) 0.02 0.008 0.85 (0.72–1.00) 0.047 0.01
1.13 (0.74–1.73) 0.56 0.47 1.34 (0.90–2.02) 0.15 0.11 1.24 (0.86–1.78) 0.25 0.19
0.89 (0.55–1.45) 0.64 0.82 1.05 (0.65–1.68) 0.84 0.72 0.97 (0.64–1.47) 0.89 0.94
0.83 (0.72–0.97) 0.02 0.004 0.84 (0.73–0.98) 0.02 0.02 0.84 (0.74–0.95) 0.006 0.002
0.68 (0.53–0.87) 0.002 0.004 0.95 (0.76–1.19) 0.66 0.89 0.81 (0.66–1.00) 0.04 0.08
0.65 (0.45–0.94) 0.02 0.02 0.73 (0.51–1.04) 0.08 0.04 0.69 (0.51–0.93) 0.02 0.008
3.46 (2.08–5.77) <0.001 4.47 (2.71–7.36) <0.001 3.96 (2.46–6.38) <0.001
1.62 (0.92–2.82) 0.09 2.52 (1.50–4.24) <0.001 2.07 (1.27–3.37) 0.003
1.79 (1.55–2.07) <0.001 2.39 (2.08–2.75) <0.001 2.09 (1.83–2.38) <0.001
2.83 (1.02–7.86) 0.04 3.74 (1.39–10.07) 0.005 3.28 (1.28–8.42) 0.009
0.67 (0.24–1.89) 0.45 1.72 (0.75–3.92) 0.20 1.19 (0.54–2.59) 0.66
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(relative reduction, 32%; absolute reduction, 1.6 
percentage points). The 2.5-mg dose of rivarox-
aban showed a nonsignificant but directionally 
consistent benefit for myocardial infarction and a 
significant reduction in the risk of stent thrombo-
sis, a finding that suggests that enhanced throm-
bin activity may play a role in these events. Thus, 
when viewed as long-term therapy after an acute 
coronary syndrome, the addition of very-low-dose 
rivaroxaban appears to be an attractive option.
Previous studies have tested rivaroxaban against 
an active comparator (e.g., warfarin or enoxaparin), 
and in general the bleeding rates between the two 
study groups have been similar. In our study, in 
which the comparator was placebo, the rates of 
bleeding were significantly higher in patients re-
0.8 1.0 1.25 2.0
Placebo BetterRivaroxaban Better
Overall
Treatment
Aspirin plus thienopyridine
Aspirin alone
Age
<65 yr
≥65 yr
Sex
Male
Female
Weight
<60 kg
≥60 to <90 kg
≥90 kg
Creatinine clearance
<50 ml/min
≥50 ml/min
Previous myocardial infarction
Yes
No
Previous stroke or TIA
Yes
No
Diabetes mellitus
Yes
No
Index event
STEMI
NSTEMI
Unstable angina
Region
North America
South America
Western Europe
Eastern Europe
Asia
Other
Combined
Rivaroxaban Hazard Ratio (95% CI)PlaceboSubgroup
0.89 (0.59–1.34)
0.57 (0.33–0.97)
0.83 (0.69–1.00)
0.90 (0.59–1.37)
0.86 (0.63–1.17)
0.92 (0.60–1.39)
0.85 (0.68–1.06)
0.82 (0.62–1.07)
0.96 (0.77–1.20)
0.78 (0.67–0.92)
0.85 (0.70–1.03)
0.82 (0.72–0.94)
1.57 (0.75–3.31)
0.83 (0.68–1.01)
0.85 (0.72–1.01)
0.85 (0.72–0.99)
0.83 (0.64–1.08)
0.88 (0.62–1.26)
0.84 (0.73–0.96)
0.83 (0.56–1.25)
0.84 (0.74–0.96)
0.77 (0.60–0.99)
0.87 (0.75–1.01)
0.84 (0.70–1.01)
0.83 (0.70–0.99)
0.86 (0.75–0.98)
0.5
0.69 (0.45–1.05)
P Value for
Interaction
376/5113
340/4760
36/353
203/3295
173/1818
270/3831
106/1282
39/462
248/3432
  89/1215
49/368
326/4691
156/1400
220/3713
  9/131
367/4982
122/1626
254/3487
172/2599
121/1321
  83/1193
27/312
35/540
34/759
181/2007
  65/1000
34/495
   626/10,229
575/9532
51/697
326/6440
300/3789
464/7627
162/2602
61/918
415/6811
150/2494
80/686
541/9411
256/2739
370/7490
31/284
595/9945
232/3268
394/6961
288/5128
201/2646
137/2455
27/562
  64/1129
  59/1482
306/4067
109/2011
61/978
no. of events/total no.
0.94
0.40
0.82
0.98
0.80
0.10
0.14
0.80
0.96
0.34
Figure 2. Risks of the Primary Efficacy End Point, According to Major Subgroup.
The primary efficacy end point consists of death from cardiovascular causes, myocardial infarction, or stroke. Among the patients who 
had a history of stroke or transient ischemic attack, 198 received aspirin only and 217 received aspirin and a thienopyridine. The latter 
was a deviation from the study protocol. NSTEMI denotes non–ST-segment elevation myocardial infarction, STEMI ST-segment eleva-
tion myocardial infarction, and TIA transient ischemic attack.
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ceiving rivaroxaban, which was expected. This 
increased bleeding risk was seen with the two 
doses of rivaroxaban, as compared with placebo, 
although the lower rivaroxaban dose resulted in 
less bleeding than the higher dose. The rates of 
adverse events, other than bleeding events, were 
similar in the combined rivaroxaban group and 
the placebo group.
In addition to rivaroxaban, other new factor Xa 
and IIa inhibitors have been evaluated in patients 
after an acute coronary syndrome. The phase 2 
programs, which evaluated rivaroxaban, apixaban, 
dabigatran, and darexaban, all showed a dose-
dependent increase in bleeding.15,16 In the ATLAS 
ACS–TIMI 46 and Apixaban for Prevention of 
Acute Ischemic Events 1 (APPRAISE-1) trials 
(NCT00313300), rivaroxaban and apixaban also 
showed trends toward a reduction in cardiovas-
cular events.4,17 APPRAISE-2 (NCT00831441) then 
tested apixaban versus placebo in a phase 3 trial, 
which showed that the addition of 5 mg of apixa-
ban twice daily to antiplatelet therapy in patients 
after an acute coronary syndrome increased the 
number of major bleeding events without a sig-
nificant reduction in the rate of recurrent is-
chemic events.18 Some of the differences in the 
findings between our study and APPRAISE-2 may 
be due in part to the patient populations. Specifi-
cally, our study was designed to exclude patients 
who had a history of ischemic stroke or transient 
ischemic attack who were to be treated with as-
pirin and a thienopyridine, a group that has not 
appeared to benefit from greater degrees of an-
tithrombotic therapy.19,20
Regarding dose regimens, a 5-mg dose of 
apix aban twice daily was tested both in patients 
with atri al fibrillation in the Apixaban for Re-
duction in Stroke and Other Thromboembolic 
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Figure 3. Cumulative Incidence of Efficacy End Points, According to Rivaroxaban Dose.
The primary efficacy end point consists of death from cardiovascular causes, myocardial infarction, or stroke. The P values are for the modified 
intention-to-treat analyses. The P values for the intention-to-treat analyses are P = 0.007 in Panel A, P = 0.01 in Panel B, P = 0.005 in Panel C, and 
P = 0.57 in Panel D. 
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Events in Atri al Fibrillation (ARISTOTLE) trial 
(NCT00412984) and in those with an acute coro-
nary syndrome in APPRAISE-2.18,21 In the trials 
evaluating rivaroxaban for stroke prophylaxis in 
patients with atrial fibrillation or treatment of 
venous thromboembolism, most patients received 
at least 20 mg per day.13,14 In our study, the tested 
doses of rivaroxaban were a quarter or one half 
of the 20-mg dose. Ultimately, the lower dose of 
rivaroxaban, but not the higher dose, resulted in 
a survival benefit. This observation is explained 
in part by the numerical increase in fatal bleed-
ing associated with the higher dose of rivaroxa-
ban. However, other consequences of nonfatal 
bleeding may also have contributed to this find-
ing.22 Within ATLAS ACS–TIMI 464 and RUBY-1 
(a phase 2 evaluation of darexaban vs. placebo in 
patients after an acute coronary syndrome) 
(NCT00994292),16 inverse dose–response relation-
ships with cardiovascular events were also ob-
served. Therefore, our study, in conjunction with 
the important observations from APPRAISE-2, 
ATLAS ACS-TIMI 46, and RUBY-1 suggests that 
in patients with a recent acute coronary syn-
drome, very low doses of an oral anticoagulant 
appear to be most favorable.
In conclusion, treatment with rivaroxaban re-
duced the risk of death from cardiovascular causes, 
myocardial infarction, or stroke in patients across 
the spectrum of acute coronary syndromes. This 
beneficial effect was accompanied by increased 
rates of bleeding. However, there was no signifi-
cant increase in the rate of fatal bleeding, and 
the twice-daily 2.5-mg dose of rivaroxaban re-
duced overall and cardiovascular mortality. Thus, 
the addition of very-low-dose anticoagulation with 
rivaroxaban may represent a new treatment strat-
egy in patients with a recent acute coronary syn-
drome.
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